HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Conron, M. Articles by Beynon, H. L C Search for Related Content PubMed PubMed Citation Articles by Conron, M. Articles by Beynon, H. L C

Thorax 2000;55:870-877 ( October )

Review series

Rare diseases  11

Churg-Strauss syndrome

Matthew Conron, Huw L C Beynon

Department of Rheumatology, Royal Free Hospital, Pond Street, London NW3 2QG, UK

Correspondence to: Dr H L C Beynon

The first 150 words of the full text of this article appear below.

	Introduction

In 1951 the pathologists Churg and Strauss identified 13 patients who presented with a clinical syndrome characterised by asthma, hypereosinophilia, and evidence of vasculitis affecting a number of organs.¹ The three main histological features found on pathological examination of these cases were extravascular granulomas, tissue eosinophilia, and necrotising vasculitis (fig 1). Most of these patients had been previously diagnosed with "periarteritis nodosa". After reviewing a number of cases of periarteritis nodosa without asthma and finding no evidence of an eosinophilic granulomatous process, Churg and Strauss suggested that their 13 cases represented a separate disease process and coined the term "allergic granulomatosis and angiitis". Later "Churg-Strauss syndrome" (CSS) became the accepted title of this distinctive form of systemic vasculitis. More recent pathological case series involving patients with CSS have highlighted the fact that not all patients have the three main histological features originally described by Churg and Strauss.^2 3 Given the absence of a . . . [Full text of this article]

This article has been cited by other articles:

				T Hauser, A Mahr, C Metzler, J Coste, R Sommerstein, W L Gross, L Guillevin, and B Hellmich The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study Thorax, August 1, 2008; 63(8): 677 - 682. [Abstract] [Full Text] [PDF]

				W. Matsuyama, H. Mitsuyama, M. Ono, Y. Shirahama, I. Higashimoto, M. Osame, and K. Arimura Discoidin domain receptor 1 contributes to eosinophil survival in an NF-{kappa}B-dependent manner in Churg-Strauss syndrome Blood, January 1, 2007; 109(1): 22 - 30. [Abstract] [Full Text] [PDF]

				H. Mitsuyama, W. Matsuyama, J. Iwakawa, I. Higashimoto, M. Watanabe, M. Osame, and K. Arimura Increased serum vascular endothelial growth factor level in churg-strauss syndrome. Chest, February 1, 2006; 129(2): 407 - 411. [Abstract] [Full Text] [PDF]

				A P Rochford, P R Smith, S J Khan, and A J G Pearson Perindopril and pulmonary eosinophilic syndrome J R Soc Med, April 1, 2005; 98(4): 163 - 165. [Full Text] [PDF]

				D. M. Hansell Small-Vessel Diseases of the Lung: CT-Pathologic Correlates Radiology, December 1, 2002; 225(3): 639 - 653. [Abstract] [Full Text] [PDF]

				A. Della Rossa, C. Baldini, A. Tavoni, A. Tognetti, D. Neglia, G. Sambuceti, R. Puccini, C. Colangelo, and S. Bombardieri Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre Rheumatology, November 1, 2002; 41(11): 1286 - 1294. [Abstract] [Full Text] [PDF]

				B D W HARRISON and D G I SCOTT Churg-Strauss syndrome Thorax, October 1, 2001; 56(10): 818a - 819. [Full Text]